{"id":7716,"date":"2026-11-16T15:58:14","date_gmt":"2026-11-16T08:58:14","guid":{"rendered":"https:\/\/tanyadna.id\/blog\/?p=7716"},"modified":"2026-11-16T15:58:16","modified_gmt":"2026-11-16T08:58:16","slug":"tes-biomarker-kanker-paru","status":"publish","type":"post","link":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/","title":{"rendered":"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"569\" src=\"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-1024x569-1.webp\" alt=\"\" class=\"wp-image-7720\" srcset=\"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-1024x569-1.webp 1024w, https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-300x167-1.webp 300w, https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-767x426-1.webp 767w, https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-.webp 1440w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Pemeriksaan histopatologi membantu menentukan diagnosis kanker paru dan menentukan jenis tumornya. Untuk merencanakan pengobatan, dokter juga akan menilai stadium kanker, yaitu seberapa luas kanker telah tumbuh dan menyebar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Berdasarkan jenis dan stadium kanker, dokter dapat meminta pemeriksaan <em>biomarker<\/em> untuk mengetahui ciri tertentu pada sel kanker. Salah satu jenisnya adalah tes molekuler, yang dapat mendeteksi perubahan genetik pada sel tumor. Sebagian perubahan tersebut mendorong pertumbuhan kanker dan dapat menjadi sasaran terapi target.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Karena profil genetik sel kanker pada setiap pasien bisa berbeda, dua pasien dengan kanker bukan sel kecil bisa mendapat pengobatan berbeda, meski sel kankernya tampak mirip di bawah mikroskop. Misalnya, tes molekuler dapat menemukan mutasi pada gen EGFR pada satu pasien dan perubahan yang disebut fusi ALK pada pasien lain.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Jika tes molekuler tidak menemukan mutasi EGFR maupun fusi ALK, dokter dapat mempertimbangkan pemeriksaan lain yaitu memeriksa PD-L1 dengan imunohistokimia. Pemeriksaan PD-L1 biasanya diperiksa melalui imunohistokimia untuk mengukur ekspresi protein, bukan dengan mencari mutasi gen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Secara umum, tes molekuler kanker paru adalah pemeriksaan terhadap DNA, RNA, atau protein tumor. Manfaatnya untuk mencari perubahan biologis yang dapat membantu menentukan pilihan pengobatan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"> Baca juga: <a href=\"https:\/\/tanyadna.id\/blog\/kras-nras-braf-kanker-kolorektal\/\">Mengenal Mutasi KRAS, NRAS, dan BRAF pada Kanker Kolorektal<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">EGFR<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">EGFR (<em>epidermal growth factor receptor<\/em>) adalah reseptor di permukaan sel yang membantu mengatur pertumbuhan dan pembelahan sel. Pada sebagian pasien kanker paru bukan sel kecil, terutama adenokarsinoma, mutasi tertentu pada gen EGFR menyebabkan sinyal pertumbuhan terus aktif sehingga sel kanker berkembang tanpa terkendali.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pemeriksaan EGFR dapat dilakukan pada jaringan tumor atau DNA tumor dalam darah, untuk mengetahui apakah terdapat mutasi yang dapat menjadi sasaran terapi target. Hasil EGFR positif tidak menunjukkan stadium atau tingkat keparahan kanker, tetapi dapat membantu dokter menentukan apakah pasien berpotensi memperoleh manfaat dari obat penghambat EGFR.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Baca juga: <a href=\"https:\/\/tanyadna.id\/blog\/gefitinib-terapi-presisi-kanker-paru-egfr\/\">Gefitinib untuk Kanker Paru dengan Mutasi EGFR<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">ALK<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">ALK (<em>anaplastic lymphoma kinase<\/em>) berperan dalam pengiriman sinyal dalam sel. Pada sebagian kanker paru bukan sel kecil, bagian dari gen ALK dapat bergabung dengan bagian dari gen lain. Perubahan ini disebut fusi gen dan dapat menghasilkan protein abnormal yang terus mengirimkan sinyal pertumbuhan pada sel kanker.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ALK dapat diperiksa melalui imunohistokimia, FISH, RT-PCR, atau <em>next-generation sequencing<\/em> (NGS). Hasil ALK positif menunjukkan bahwa tumor mungkin memiliki perubahan yang dapat ditargetkan dengan inhibitor ALK, tetapi dalam pemilihan terapi dokter tetap mempertimbangkan stadium kanker, kondisi pasien, metode pemeriksaan, dan pengobatan yang pernah diterima.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">PD-L1<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">PD-L1 (<em>programmed death-ligand 1<\/em>) adalah protein pada permukaan sebagian sel tumor dan sel imun yang dapat membantu kanker menghindari serangan sistem kekebalan tubuh. Pemeriksaan PD-L1 biasanya dilakukan melalui imunohistokimia dan dapat dilaporkan sebagai <em>Tumor Proportion Score<\/em> (TPS), yaitu persentase sel tumor yang menunjukkan pewarnaan PD-L1.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hasil ini membantu dokter menilai kemungkinan manfaat imunoterapi, tetapi ekspresi PD-L1 yang tinggi tidak menjamin bahwa terapi tersebut pasti berhasil. Berbeda dari EGFR dan ALK, PD-L1 umumnya merupakan pemeriksaan ekspresi protein, bukan tes mutasi gen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Baca juga: <a href=\"https:\/\/tanyadna.id\/blog\/oncogenomics-dna-kanker\/\">DNA dan Diagnosis Kanker<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Interpretasi Tes Molekuler Kanker Paru<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Interpretasi ketiga tes harus dilakukan secara terpadu:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">EGFR positif berarti ditemukan perubahan (mutasi) pada gen EGFR di sel kanker. Laporan pemeriksaan menyebutkan jenis mutasinya, yang juga disebut varian. Jenis variannya perlu diperiksa karena tidak semua mutasi memiliki makna atau pilihan terapi yang sama.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ALK positif menunjukkan adanya ekspresi atau perubahan ALK, seperti penyusunan ulang atau fusi gen, yang dalam konteks klinis tertentu dapat mendukung penggunaan terapi target ALK.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">PD-L1 dinilai berdasarkan persentase ekspresi protein pada sel tumor, biasanya sebagai <em>Tumor Proportion Score<\/em> (TPS), dengan kategori umum kurang dari 1%, 1\u201349%, dan 50% atau lebih untuk membantu menilai peran imunoterapi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hasil positif EGFR atau ALK tidak menunjukkan stadium maupun tingkat keganasan kanker, sedangkan PD-L1 tinggi tidak menjamin imunoterapi pasti berhasil. Hasil ketiganya tidak boleh ditafsirkan secara terpisah dan harus dibahas bersama dokter yang menangani, karena metode, kualitas sampel, jenis kanker, stadium, kondisi pasien, dan <em>biomarker<\/em> lain turut memengaruhi keputusan,<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Kesimpulan<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Tes molekuler kanker paru membantu dokter memahami perubahan biologis yang mendorong pertumbuhan tumor dan memilih pengobatan lebih terarah. EGFR mencari mutasi yang dapat menjadi target terapi. ALK menilai penyusunan ulang atau fusi gen yang mengaktifkan sinyal pertumbuhan. Sementara, PD-L1 mengukur ekspresi protein untuk membantu mengevaluasi peran imunoterapi, meskipun secara teknis bukan tes mutasi gen.<\/p>\n\n\n\n<div style=\"border-top-left-radius:16px;border-top-right-radius:16px;border-bottom-left-radius:16px;border-bottom-right-radius:16px;color:#0369a1;background-color:#e0f2fe;margin-top:var(--wp--preset--spacing--40);margin-right:var(--wp--preset--spacing--40);margin-bottom:var(--wp--preset--spacing--40);margin-left:var(--wp--preset--spacing--40);padding-top:var(--wp--preset--spacing--40);padding-right:var(--wp--preset--spacing--40);padding-bottom:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40)\" class=\"wp-block-roelmagdaleno-callout-block has-text-color has-background is-layout-flex wp-container-roelmagdaleno-callout-block-is-layout-4b05851f wp-block-roelmagdaleno-callout-block-is-layout-flex\"><div>\n<p class=\"wp-block-paragraph\"><strong>Disclaimer<\/strong><br>Informasi ini bertujuan edukasi dan tidak menggantikan konsultasi langsung dengan tenaga medis profesional. Jika Anda memiliki gejala yang mengkhawatirkan, segera konsultasikan ke dokter.<\/p>\n<\/div><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tes molekuler kanker paru membantu dokter memahami perubahan biologis yang mendorong pertumbuhan tumor dan memilih pengobatan lebih terarah. <\/p>\n","protected":false},"author":38,"featured_media":7720,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_zengeo_excluded":false,"_zengeo_faq":[],"_zengeo_takeaways":[],"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1 -<\/title>\n<meta name=\"description\" content=\"Pahami tes biomarker kanker paru, termasuk EGFR, ALK, dan PD-L1, serta perannya dalam memilih terapi presisi.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1 -\" \/>\n<meta property=\"og:description\" content=\"Pahami tes biomarker kanker paru, termasuk EGFR, ALK, dan PD-L1, serta perannya dalam memilih terapi presisi.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T08:58:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-16T08:58:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"dr. Intan Nefia Alamanda, SpPA\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"dr. Intan Nefia Alamanda, SpPA\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/\"},\"author\":{\"name\":\"dr. Intan Nefia Alamanda, SpPA\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#\\\/schema\\\/person\\\/7ac04e15dc6be76d22a834bba61f461a\"},\"headline\":\"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1\",\"datePublished\":\"2026-11-16T08:58:14+00:00\",\"dateModified\":\"2026-11-16T08:58:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/\"},\"wordCount\":706,\"commentCount\":2,\"publisher\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/marker-kanker-paru-.webp\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/\",\"url\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/\",\"name\":\"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1 -\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/marker-kanker-paru-.webp\",\"datePublished\":\"2026-11-16T08:58:14+00:00\",\"dateModified\":\"2026-11-16T08:58:16+00:00\",\"description\":\"Pahami tes biomarker kanker paru, termasuk EGFR, ALK, dan PD-L1, serta perannya dalam memilih terapi presisi.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/marker-kanker-paru-.webp\",\"contentUrl\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/marker-kanker-paru-.webp\",\"width\":1440,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/tes-biomarker-kanker-paru\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/\",\"name\":\"Tanyadna\",\"description\":\"Informasi Tes DNA dan Kesehatan Genetik\",\"publisher\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#organization\"},\"alternateName\":\"Tanyadna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#organization\",\"name\":\"Tanyadna\",\"alternateName\":\"https:\\\/\\\/tanyadna.id\\\/id\\\/\",\"url\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cropped-tanyadnalogo-scaled-2.png\",\"contentUrl\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cropped-tanyadnalogo-scaled-2.png\",\"width\":2272,\"height\":756,\"caption\":\"Tanyadna\"},\"image\":{\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/#\\\/schema\\\/person\\\/7ac04e15dc6be76d22a834bba61f461a\",\"name\":\"dr. Intan Nefia Alamanda, SpPA\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/cropped-intan_nefia-96x96.png\",\"url\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/cropped-intan_nefia-96x96.png\",\"contentUrl\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/cropped-intan_nefia-96x96.png\",\"caption\":\"dr. Intan Nefia Alamanda, SpPA\"},\"url\":\"https:\\\/\\\/tanyadna.id\\\/blog\\\/author\\\/intan-alamanda\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1 -","description":"Pahami tes biomarker kanker paru, termasuk EGFR, ALK, dan PD-L1, serta perannya dalam memilih terapi presisi.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/","og_locale":"en_US","og_type":"article","og_title":"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1 -","og_description":"Pahami tes biomarker kanker paru, termasuk EGFR, ALK, dan PD-L1, serta perannya dalam memilih terapi presisi.","og_url":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/","article_published_time":"2026-11-16T08:58:14+00:00","article_modified_time":"2026-11-16T08:58:16+00:00","og_image":[{"width":1440,"height":800,"url":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-.webp","type":"image\/webp"}],"author":"dr. Intan Nefia Alamanda, SpPA","twitter_card":"summary_large_image","twitter_misc":{"Written by":"dr. Intan Nefia Alamanda, SpPA","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/#article","isPartOf":{"@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/"},"author":{"name":"dr. Intan Nefia Alamanda, SpPA","@id":"https:\/\/tanyadna.id\/blog\/#\/schema\/person\/7ac04e15dc6be76d22a834bba61f461a"},"headline":"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1","datePublished":"2026-11-16T08:58:14+00:00","dateModified":"2026-11-16T08:58:16+00:00","mainEntityOfPage":{"@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/"},"wordCount":706,"commentCount":2,"publisher":{"@id":"https:\/\/tanyadna.id\/blog\/#organization"},"image":{"@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/#primaryimage"},"thumbnailUrl":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-.webp","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/","url":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/","name":"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1 -","isPartOf":{"@id":"https:\/\/tanyadna.id\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/#primaryimage"},"image":{"@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/#primaryimage"},"thumbnailUrl":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-.webp","datePublished":"2026-11-16T08:58:14+00:00","dateModified":"2026-11-16T08:58:16+00:00","description":"Pahami tes biomarker kanker paru, termasuk EGFR, ALK, dan PD-L1, serta perannya dalam memilih terapi presisi.","breadcrumb":{"@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/#primaryimage","url":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-.webp","contentUrl":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/marker-kanker-paru-.webp","width":1440,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/tanyadna.id\/blog\/tes-biomarker-kanker-paru\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tanyadna.id\/blog\/"},{"@type":"ListItem","position":2,"name":"Tes Molekuler Kanker Paru: EGFR, ALK, dan PD-L1"}]},{"@type":"WebSite","@id":"https:\/\/tanyadna.id\/blog\/#website","url":"https:\/\/tanyadna.id\/blog\/","name":"Tanyadna","description":"Informasi Tes DNA dan Kesehatan Genetik","publisher":{"@id":"https:\/\/tanyadna.id\/blog\/#organization"},"alternateName":"Tanyadna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tanyadna.id\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tanyadna.id\/blog\/#organization","name":"Tanyadna","alternateName":"https:\/\/tanyadna.id\/id\/","url":"https:\/\/tanyadna.id\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tanyadna.id\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/09\/cropped-tanyadnalogo-scaled-2.png","contentUrl":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/09\/cropped-tanyadnalogo-scaled-2.png","width":2272,"height":756,"caption":"Tanyadna"},"image":{"@id":"https:\/\/tanyadna.id\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tanyadna.id\/blog\/#\/schema\/person\/7ac04e15dc6be76d22a834bba61f461a","name":"dr. Intan Nefia Alamanda, SpPA","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/cropped-intan_nefia-96x96.png","url":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/cropped-intan_nefia-96x96.png","contentUrl":"https:\/\/tanyadna.id\/blog\/wp-content\/uploads\/2026\/11\/cropped-intan_nefia-96x96.png","caption":"dr. Intan Nefia Alamanda, SpPA"},"url":"https:\/\/tanyadna.id\/blog\/author\/intan-alamanda\/"}]}},"_links":{"self":[{"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/posts\/7716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/comments?post=7716"}],"version-history":[{"count":2,"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/posts\/7716\/revisions"}],"predecessor-version":[{"id":7722,"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/posts\/7716\/revisions\/7722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/media\/7720"}],"wp:attachment":[{"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/media?parent=7716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/categories?post=7716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tanyadna.id\/blog\/wp-json\/wp\/v2\/tags?post=7716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}